Table 5.
Weights Assigned to Conditions in the Chronic Disease Score (Von Korff, Wagner, and Saunders 1992) and weights derived from New Jersey Medicare Data (N=235,881) for the Same Conditions
| Conditions and Medications Attributed to These Conditions According to Von Korff et al. (1992) | Prevalence in NJ in % | Original CDS-1 Weights | NJ Odds Ratio Estimates* | 95% Confidence Interval | Assigned NJ Medicare Weights** | ||
|---|---|---|---|---|---|---|---|
| Heart disease: | (1) Anti-coagulants, hemostatics, | one class | 42.3 | 3 | 1.45 | (1.39–1.51) | 1 |
| (2) Cardiac agents, ACE inhibitors, | two classes | 16.3 | 4 | 2.53 | (2.42–2.64) | 3 | |
| (3) Loop diuretics | three classes | 2.3 | 5 | 3.14 | (2.89–3.41) | 4 | |
| Respiratory illness: | (1) Isoproterenol, (2) Beta-adrenergic | one class | 7.0 | 2 | 1.49 | (1.41–1.58) | 1 |
| (3) Xanthines, (4) Bronchodilators and mucolytic but excluding cromolyn, (5) Epinephrine | two classes | 4.6 | 3 | 1.89 | (1.77–2.02) | 2 | |
| Asthma, rheumatism: | Glucocorticoids | 8.7 | 3 | 1.32 | (1.25–1.40) | 1 | |
| Rheumatoid arthritis: | Gold salts | 0.1 | 3 | 0.80 | (0.40–1.61) | −1 | |
| Cancer: | Antineoplastics | 3.1 | 3 | 2.18 | (2.03–2.34) | 3 | |
| Parkinson's disease: | L-dopa | 1.8 | 3 | 2.04 | (1.87–2.24) | 2 | |
| Hypertension: | (1) Antihypertensives (except ACEI) or calcium channel blockers | class (1) | 18.4 | 2 | 0.95 | (0.91–0.99) | 0 |
| (2) Beta blockers, diuretics | class (2) not (1) | 10.4 | 1 | 1.03 | (0.97–1.08) | 0 | |
| Diabetes: | Insulin, oral hypoglycemics | 16.2 | 2 | 1.42 | (1.36–1.48) | 1 | |
| Epilepsy: | Anticonvulsants | 4.0 | 2 | 1.95 | (1.83–2.08) | 2 | |
| Asthma, rhinitis: | Cromolyn | 0.6 | 2 | 0.54 | (0.43–0.69) | −2 | |
| Acne: | (1) Antiacne tretinoin, (2) topical macrolides | 0.2 | 1 | 0.49 | (0.28–0.86) | −2 | |
| Ulcers: | Cimetidine | 27.7 | 1 | 1.30 | (1.25–1.34) | 1 | |
| Glaucoma: | Ophthalmic miotics | 10.1 | 1 | 0.94 | (0.89–0.99) | 0 | |
| Gout, hyperuricemia: | Uric acid agents | 3.1 | 1 | 1.16 | (1.08–1.26) | 0 | |
| High cholesterol: | Antilipidemics | 10.0 | 1 | 0.59 | (0.55–0.63) | −2 | |
| Migraines: | Ergot derivates | 0.7 | 1 | 0.84 | (0.69–1.03) | −1 | |
| Tuberculosis: | Antitubercular agents | 0.2 | 1 | 1.81 | (1.38–2.38) | 2 | |
*
Odds ratio of dying during the follow-up comparing patients with the condition versus subjects without.
**
A 35% increase in risk of dying is reflected in a one-point increase in weights (see appendix for scoring rule).